LadRx Corporation (LADX)
USD 1.49
(-2.61%)
USD 1.49
(-2.61%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 400.44 Thousand USD | 109.53% |
| 2022 | -4.2 Million USD | 68.12% |
| 2021 | -13.17 Million USD | -96.65% |
| 2020 | -6.7 Million USD | 6.45% |
| 2019 | -7.16 Million USD | 43.66% |
| 2018 | -12.71 Million USD | 63.66% |
| 2017 | -34.98 Million USD | 31.09% |
| 2016 | -50.77 Million USD | 13.34% |
| 2015 | -58.58 Million USD | -94.53% |
| 2014 | -30.11 Million USD | 36.57% |
| 2013 | -47.48 Million USD | -164.34% |
| 2012 | -17.96 Million USD | -24.54% |
| 2011 | -14.42 Million USD | -3631.45% |
| 2010 | 408.46 Thousand USD | 108.51% |
| 2009 | -4.8 Million USD | 82.25% |
| 2008 | -27.04 Million USD | -23.56% |
| 2007 | -21.88 Million USD | -30.67% |
| 2006 | -16.75 Million USD | -10.99% |
| 2005 | -15.09 Million USD | 7.93% |
| 2004 | -16.39 Million USD | 8.14% |
| 2003 | -17.84 Million USD | -188.95% |
| 2002 | -6.17 Million USD | -563.09% |
| 2001 | -931.34 Thousand USD | -167.55% |
| 2000 | -348.1 Thousand USD | 97.69% |
| 1999 | -15.04 Million USD | -138.75% |
| 1998 | -6.3 Million USD | -5.0% |
| 1997 | -6 Million USD | -3.45% |
| 1996 | -5.8 Million USD | 45.79% |
| 1995 | -10.7 Million USD | -38.96% |
| 1994 | -7.7 Million USD | -140.63% |
| 1993 | -3.2 Million USD | -3100.0% |
| 1992 | -100 Thousand USD | -104.0% |
| 1991 | 2.5 Million USD | 377.78% |
| 1990 | -900 Thousand USD | 81.25% |
| 1989 | -4.8 Million USD | -2.13% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -1.28 Million USD | -787.06% |
| 2024 Q1 | 186.73 Thousand USD | 121.76% |
| 2023 Q1 | -1.07 Million USD | -13.8% |
| 2023 Q4 | -858.03 Thousand USD | -5.15% |
| 2023 Q3 | -815.98 Thousand USD | -125.91% |
| 2023 Q2 | 3.14 Million USD | 393.06% |
| 2023 FY | 400.44 Thousand USD | 109.53% |
| 2022 FY | -4.2 Million USD | 68.12% |
| 2022 Q1 | -1.29 Million USD | 85.64% |
| 2022 Q2 | -793.77 Thousand USD | 38.75% |
| 2022 Q4 | -944.2 Thousand USD | 19.07% |
| 2022 Q3 | -1.16 Million USD | -46.98% |
| 2021 Q1 | -1.27 Million USD | 9.38% |
| 2021 Q3 | -1.69 Million USD | -44.18% |
| 2021 Q2 | -1.17 Million USD | 8.09% |
| 2021 Q4 | -9.02 Million USD | -432.45% |
| 2021 FY | -13.17 Million USD | -96.65% |
| 2020 Q2 | -1.34 Million USD | -14.38% |
| 2020 Q4 | -1.41 Million USD | 49.12% |
| 2020 Q1 | -1.17 Million USD | 60.79% |
| 2020 Q3 | -2.77 Million USD | -106.83% |
| 2020 FY | -6.7 Million USD | 6.45% |
| 2019 Q3 | -1.47 Million USD | -15.46% |
| 2019 FY | -7.16 Million USD | 43.66% |
| 2019 Q4 | -2.99 Million USD | -103.23% |
| 2019 Q2 | -1.27 Million USD | 10.62% |
| 2019 Q1 | -1.42 Million USD | 38.99% |
| 2018 Q2 | -3 Million USD | 26.16% |
| 2018 Q3 | -3.29 Million USD | -9.35% |
| 2018 Q4 | -2.33 Million USD | 28.98% |
| 2018 Q1 | -4.07 Million USD | 8.61% |
| 2018 FY | -12.71 Million USD | 63.66% |
| 2017 FY | -34.98 Million USD | 31.09% |
| 2017 Q2 | -14.35 Million USD | -30.01% |
| 2017 Q1 | -11.04 Million USD | -43.95% |
| 2017 Q3 | -5.12 Million USD | 64.31% |
| 2017 Q4 | -4.45 Million USD | 12.97% |
| 2016 Q3 | -12.17 Million USD | 33.4% |
| 2016 Q2 | -18.28 Million USD | -44.59% |
| 2016 Q4 | -7.67 Million USD | 36.98% |
| 2016 FY | -50.77 Million USD | 13.34% |
| 2016 Q1 | -12.64 Million USD | 43.31% |
| 2015 Q1 | -17.52 Million USD | -30.41% |
| 2015 Q4 | -22.3 Million USD | -215.3% |
| 2015 FY | -58.58 Million USD | -94.53% |
| 2015 Q2 | -11.68 Million USD | 33.31% |
| 2015 Q3 | -7.07 Million USD | 39.48% |
| 2014 FY | -30.11 Million USD | 36.57% |
| 2014 Q4 | -13.43 Million USD | -138.88% |
| 2014 Q3 | -5.62 Million USD | 64.21% |
| 2014 Q2 | -15.71 Million USD | -437.0% |
| 2014 Q1 | 4.66 Million USD | 117.14% |
| 2013 Q3 | -9.98 Million USD | -191.55% |
| 2013 Q2 | -3.42 Million USD | 50.13% |
| 2013 Q4 | -27.21 Million USD | -172.73% |
| 2013 Q1 | -6.86 Million USD | -278.32% |
| 2013 FY | -47.48 Million USD | -164.34% |
| 2012 Q3 | 1.58 Million USD | 111.94% |
| 2012 FY | -17.96 Million USD | -24.54% |
| 2012 Q4 | 3.84 Million USD | 142.98% |
| 2012 Q1 | -10.13 Million USD | -126.66% |
| 2012 Q2 | -13.26 Million USD | -30.86% |
| 2011 Q3 | -557.76 Thousand USD | 82.12% |
| 2011 FY | -14.42 Million USD | -3631.45% |
| 2011 Q4 | -4.47 Million USD | -701.67% |
| 2011 Q1 | -6.27 Million USD | -251.61% |
| 2011 Q2 | -3.12 Million USD | 50.28% |
| 2010 FY | 408.46 Thousand USD | 108.51% |
| 2010 Q1 | -610.52 Thousand USD | 75.22% |
| 2010 Q4 | 4.13 Million USD | 193.77% |
| 2010 Q2 | 1.29 Million USD | 311.93% |
| 2010 Q3 | -4.41 Million USD | -441.15% |
| 2009 Q4 | -2.46 Million USD | -163.79% |
| 2009 Q2 | -2.22 Million USD | 43.99% |
| 2009 FY | -4.8 Million USD | 82.25% |
| 2009 Q1 | -3.97 Million USD | -12.53% |
| 2009 Q3 | 3.86 Million USD | 273.56% |
| 2008 Q2 | -5.82 Million USD | -8.42% |
| 2008 FY | -27.04 Million USD | -23.56% |
| 2008 Q4 | -3.53 Million USD | 71.33% |
| 2008 Q3 | -12.31 Million USD | -111.39% |
| 2008 Q1 | -5.37 Million USD | 16.81% |
| 2007 Q4 | -6.45 Million USD | -40.51% |
| 2007 FY | -21.88 Million USD | -30.67% |
| 2007 Q1 | -4.54 Million USD | -9.59% |
| 2007 Q2 | -6.23 Million USD | -37.14% |
| 2007 Q3 | -4.59 Million USD | 26.26% |
| 2006 Q4 | -4.14 Million USD | -39.56% |
| 2006 Q2 | -5.46 Million USD | -31.18% |
| 2006 Q3 | -2.97 Million USD | 45.62% |
| 2006 Q1 | -4.16 Million USD | -16.88% |
| 2006 FY | -16.75 Million USD | -10.99% |
| 2005 Q4 | -3.56 Million USD | -2.07% |
| 2005 Q3 | -3.49 Million USD | 22.55% |
| 2005 Q2 | -4.5 Million USD | -27.86% |
| 2005 Q1 | -3.52 Million USD | 38.8% |
| 2005 FY | -15.09 Million USD | 7.93% |
| 2004 Q1 | -3.77 Million USD | 57.96% |
| 2004 Q4 | -5.76 Million USD | -106.1% |
| 2004 Q2 | -4.06 Million USD | -7.61% |
| 2004 Q3 | -2.79 Million USD | 31.15% |
| 2004 FY | -16.39 Million USD | 8.14% |
| 2003 Q1 | -913.99 Thousand USD | 64.66% |
| 2003 FY | -17.84 Million USD | -188.95% |
| 2003 Q4 | -8.97 Million USD | -208.75% |
| 2003 Q3 | -2.9 Million USD | 42.39% |
| 2003 Q2 | -5.04 Million USD | -452.13% |
| 2002 Q3 | -2.47 Million USD | -166.34% |
| 2002 Q2 | -930.81 Thousand USD | -419.3% |
| 2002 Q1 | -179.24 Thousand USD | -107.32% |
| 2002 Q4 | -2.58 Million USD | -4.33% |
| 2002 FY | -6.17 Million USD | -563.09% |
| 2001 Q3 | -1 Million USD | 17.82% |
| 2001 Q1 | -1.15 Million USD | -199.69% |
| 2001 Q4 | 2.44 Million USD | 344.22% |
| 2001 FY | -931.34 Thousand USD | -167.55% |
| 2001 Q2 | -1.21 Million USD | -5.38% |
| 2000 Q3 | -606.19 Thousand USD | -23197.16% |
| 2000 Q1 | -900.09 Thousand USD | 78.78% |
| 2000 FY | -348.1 Thousand USD | 97.69% |
| 2000 Q4 | 1.16 Million USD | 291.49% |
| 2000 Q2 | -2602.00 USD | 99.71% |
| 1999 Q2 | -2.7 Million USD | 18.18% |
| 1999 FY | -15.04 Million USD | -138.75% |
| 1999 Q4 | -4.24 Million USD | 13.45% |
| 1999 Q3 | -4.9 Million USD | -81.48% |
| 1999 Q1 | -3.3 Million USD | 53.52% |
| 1998 Q4 | -7.1 Million USD | -255.0% |
| 1998 FY | -6.3 Million USD | -5.0% |
| 1998 Q1 | -800 Thousand USD | 55.56% |
| 1998 Q2 | 3.6 Million USD | 550.0% |
| 1998 Q3 | -2 Million USD | -155.56% |
| 1997 Q1 | -700 Thousand USD | 68.18% |
| 1997 Q4 | -1.8 Million USD | -38.46% |
| 1997 Q3 | -1.3 Million USD | 43.48% |
| 1997 Q2 | -2.3 Million USD | -228.57% |
| 1997 FY | -6 Million USD | -3.45% |
| 1996 Q3 | -1.1 Million USD | 0.0% |
| 1996 Q2 | -1.1 Million USD | 15.38% |
| 1996 Q1 | -1.3 Million USD | 35.0% |
| 1996 FY | -5.8 Million USD | 45.79% |
| 1996 Q4 | -2.2 Million USD | -100.0% |
| 1995 Q3 | -2 Million USD | 39.39% |
| 1995 Q2 | -3.3 Million USD | 2.94% |
| 1995 Q1 | -3.4 Million USD | -47.83% |
| 1995 FY | -10.7 Million USD | -38.96% |
| 1995 Q4 | -2 Million USD | 0.0% |
| 1994 Q1 | -1.6 Million USD | 20.0% |
| 1994 Q3 | -1.9 Million USD | 5.0% |
| 1994 Q2 | -2 Million USD | -25.0% |
| 1994 FY | -7.7 Million USD | -140.63% |
| 1994 Q4 | -2.3 Million USD | -21.05% |
| 1993 Q3 | -1 Million USD | -400.0% |
| 1993 Q1 | 200 Thousand USD | 150.0% |
| 1993 Q2 | -200 Thousand USD | -200.0% |
| 1993 Q4 | -2 Million USD | -100.0% |
| 1993 FY | -3.2 Million USD | -3100.0% |
| 1992 Q4 | -400 Thousand USD | -500.0% |
| 1992 Q3 | 100 Thousand USD | -50.0% |
| 1992 Q2 | 200 Thousand USD | 0.0% |
| 1992 Q1 | - USD | 100.0% |
| 1992 FY | -100 Thousand USD | -104.0% |
| 1991 FY | 2.5 Million USD | 377.78% |
| 1991 Q4 | -200 Thousand USD | -120.0% |
| 1991 Q1 | 600 Thousand USD | 700.0% |
| 1991 Q2 | 1.1 Million USD | 83.33% |
| 1991 Q3 | 1 Million USD | -9.09% |
| 1990 Q4 | -100 Thousand USD | 50.0% |
| 1990 Q3 | -200 Thousand USD | 0.0% |
| 1990 Q1 | -600 Thousand USD | 62.5% |
| 1990 Q2 | - USD | 100.0% |
| 1990 FY | -900 Thousand USD | 81.25% |
| 1989 FY | -4.8 Million USD | -2.13% |
| 1989 Q3 | -600 Thousand USD | 0.0% |
| 1989 Q2 | - USD | 0.0% |
| 1989 Q1 | - USD | 0.0% |
| 1989 Q4 | -1.6 Million USD | -166.67% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 129.986% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 105.735% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 99.244% |
| Nascent Biotech, Inc. | -2.08 Million USD | 119.181% |
| Rebus Holdings, Inc. | -1.02 Million USD | 139.259% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 99.385% |
| Qrons Inc. | -789.34 Thousand USD | 150.731% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 163.32% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 100.64% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 196.381% |
| Skye Bioscience, Inc. | -37.64 Million USD | 101.064% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 100.534% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 106.089% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 246.467% |
| SQZ Biotechnologies Company | -79.46 Million USD | 100.504% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 113.845% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 121.996% |
| Mesoblast Limited | -87.95 Million USD | 100.455% |
| Marizyme, Inc. | -65.34 Million USD | 100.613% |
| Genus plc | 7.9 Million USD | 94.931% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 103.677% |
| Pharming Group N.V. | -10.54 Million USD | 103.796% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 118.455% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 110.793% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 104.528% |
| ContraFect Corporation | -65.15 Million USD | 100.615% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 108.196% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 123.181% |
| IMV Inc. | -36.48 Million USD | 101.098% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 104.968% |
| MultiCell Technologies, Inc. | -380.07 USD | 105460.328% |
| ONE Bio Corp. | 8.67 Million USD | 95.385% |
| Accustem Sciences Inc. | -3.74 Million USD | 110.689% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 100.775% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 131.602% |
| Q BioMed Inc. | -2.05 Million USD | 119.514% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 110.727% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 116.819% |
| Biomind Labs Inc. | -1.21 Million USD | 132.977% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 100.67% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 112.91% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 105.067% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 120.543% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | 2773.898% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 102.523% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 106.884% |
| GB Sciences, Inc. | -1.36 Million USD | 129.408% |
| Alpha Cognition Inc. | -13.77 Million USD | 102.908% |
| HST Global, Inc. | -146.21 Thousand USD | 373.882% |
| CSL Limited | 2.64 Billion USD | 99.985% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 122.82% |
| Halberd Corporation | -79.67 Thousand USD | 602.589% |
| Enzolytics Inc. | -2.17 Million USD | 118.396% |
| Agentix Corp. | -1.37 Million USD | 129.14% |
| Resverlogix Corp. | -3.61 Million USD | 111.093% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 112.627% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -295.05 Million USD | 100.136% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | -308.615% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 94.217% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 110.079% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 113.233% |
| AVAX Technologies, Inc. | -6.41 Million USD | 106.244% |
| Zenith Capital Corp. | -10.59 Million USD | 103.779% |
| Genscript Biotech Corporation | -95.47 Million USD | 100.419% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | 1822.928% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 109.659% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | 762.54% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 119.971% |
| Kadimastem Ltd | -3.3 Million USD | 112.107% |
| Helix BioMedix, Inc. | -1.05 Million USD | 137.919% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 110.486% |
| BioStem Technologies, Inc. | -8.48 Million USD | 104.721% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 190.727% |
| Cell Source, Inc. | -5.32 Million USD | 107.525% |
| Regen BioPharma, Inc. | 1.02 Million USD | 60.875% |
| Regen BioPharma, Inc. | 1.02 Million USD | 60.875% |
| NovAccess Global Inc. | -4.76 Million USD | 108.396% |
| Affymax, Inc. | -14.42 Million USD | 102.776% |
| Itoco Inc. | -1.86 Million USD | 121.426% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 109.014% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 123.993% |
| Mobile Lads Corp. | -2.26 Million USD | 117.693% |
| CytoDyn Inc. | -49.84 Million USD | 100.803% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | 606.678% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 275.535% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 142.531% |
| SYBLEU INC | -180.3 Thousand USD | 322.093% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 124.83% |
| International Stem Cell Corporation | -131 Thousand USD | 405.682% |
| Bioxytran, Inc. | -4.28 Million USD | 109.356% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | 837.845% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 115.826% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 100.833% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 118.942% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 151.281% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 112.64% |
| Neutra Corp. | -233.46 Thousand USD | 271.522% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 101.974% |
| PureTech Health plc | -65.69 Million USD | 100.61% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 101.883% |
| IXICO plc | -1.17 Million USD | 133.993% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 104.034% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 100.701% |
| CSL Limited | 2.64 Billion USD | 99.985% |
| Cellectis S.A. | -103.17 Million USD | 100.388% |